The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Critical review of antipsychotic polypharmacy in the treatment of schizophrenia
Abstract
Antipsychotic polypharmacy remains prevalent; it has probably increased for the treatment of schizophrenia in real-world clinical settings. The current evidence suggests some clinical benefits of antipsychotic polypharmacy, such as better symptom control with clozapine plus another antipsychotic, and a reversal of metabolic side-effects with a concomitant use of aripiprazole. On the other hand, the interpretation of findings in the literature should be made conservatively in light of the paucity of good studies and potentially serious side-effects. Also, although the available data are still limited, two smaller-scale clinical trials provide preliminary evidence that converting antipsychotic polypharmacy to monotherapy could be a valid and reasonable treatment option. Several studies have explored strategies to change physicians' antipsychotic polypharmacy prescribing behaviours. These have revealed that, while the impact of purely educational interventions may be limited, more aggressive procedures such as directly notifying physicians by letters or phone calls can be more effective in reducing antipsychotic polypharmacy. In conclusion, antipsychotic polypharmacy can work for some clinically difficult conditions; however, it should be the exception rather than the rule and may be avoidable in many patients. More importantly, the paucity of the data clearly emphasizes the need for further investigations on not only advantages and disadvantages of antipsychotic polypharmacy, but also regarding effective interventions in already prescribed polypharmacy regimens.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Atypical antipsychotic drugs and the risk of sudden cardiac death
Ray, W. A., Chung, C. P., Murray, K. T., Hall, K., & Stein, C. M. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0806994 · Cited by 1,194
Royal Australian And New Zealand College Of Psychiatrists Clinical Practice Guidelines Team For The Treatment Of Schizophrenia And Related Disorders (2005) · Australian & New Zealand Journal of Psychiatry · doi:10.1080/j.1440-1614.2005.01516.x · Cited by 435
Schizophrenia, neuroleptic medication and mortality
Joukamaa, M., Heliövaara, M., Knekt, P., Aromaa, A., Raitasalo, R., & Lehtinen, V. (2006) · British Journal of Psychiatry · doi:10.1192/bjp.188.2.122 · Cited by 395 · cited 1×
“A population-based study of a cohort of 7217 Finns demonstrated similar findings (Joukamaa et al. 2006).”
ResultClozapine alone versus clozapine and risperidone with refractory schizophrenia
Honer, W. G., Thornton, A. E., Chen, E. Y. H., Chan, R. C. K., Wong, J. O. Y., Bergmann, A., Falkai, P., Pomarol-Clotet, E., McKenna, P. J., Stip, E., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053222 · Cited by 277 · cited 1×
“In the largest sample evaluated so far, Honer et al. (2006) compared the efficacy of clozapine combined with risperidone to clozapine plus placebo in 68 patients with schizophrenia who had previously failed to respond to clozapine monotherapy in an 8 wk double blind RCT.”
BackgroundAuquier, P., Lançon, C., Rouillon, F., Lader, M., & Holmes, C. (2006) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1325 · Cited by 249 · cited 2×
“…prospective study that included a cohort of 88 in-patients with schizophrenia in Ireland demonstrated that 39 of the 88 patients died; the maximum number of antipsychotics given concurrently for each individual predicted reduced survival (RR 2.46, 95% CI 1.10–5.47, p=0.03 ; Waddington et al. 1998).”
BackgroundInfluential
Cited by
Barnes, T. R., Drake, R., Paton, C., Cooper, S. J., Deakin, B., Ferrier, I. N., Gregory, C. J., Haddad, P. M., Howes, O. D., Jones, I., et al. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881119889296 · Cited by 606
Stratified medicine for mental disorders
Schumann, G., Binder, E. B., Holte, A., de Kloet, E. R., Oedegaard, K. J., Robbins, T. W., Walker-Tilley, T. R., Bitter, I., Brown, V. J., Buitelaar, J., et al. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.09.010 · Cited by 186
Self-citationShared decision making for psychiatric medication management: beyond the micro‐social
Morant, N., Kaminskiy, E., & Ramon, S. (2016) · Health Expectations · doi:10.1111/hex.12392 · Cited by 129
Windfuhr, K., While, D., Kapur, N., Ashcroft, D. M., Kontopantelis, E., Carr, M. J., Shaw, J., Appleby, L., & Webb, R. T. (2016) · Psychological Medicine · doi:10.1017/s0033291716001823 · Cited by 34
“There has been an increasing tendency towards complex prescribing, sometimes in the absence of evidence indicating improved patient outcomes (Mojtabai & Olfson, 2010; Fleischhacker & Uchida, 2014).”
BackgroundCorrell, C. U., Sliwa, J. K., Najarian, D. M., & Saklad, S. R. (2019) · CNS Spectrums · doi:10.1017/s1092852918001098 · Cited by 27
Metadata
- Authors
- Fleischhacker, W. W., & Uchida, H.
- Venue
- The International Journal of Neuropsychopharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-05-02
- Volume
- 17
- Issue
- 07
- Pages
- 1083-1093
- ISSN
- 1461-1457 (ISSN-L)
- 1469-5111
- OpenAlex
- W2007189458
- Cited by
- 177
- References
- 5
- FWCI
- 7.17
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Critical review of antipsychotic polypharmacy in the treatment of schizophrenia. https://app.cochat.ai/papers/10.1017/s1461145712000399
- The paper
- Fleischhacker, W. W., & Uchida, H. (2014). Critical review of antipsychotic polypharmacy in the treatment of schizophrenia. The International Journal of Neuropsychopharmacology. https://doi.org/10.1017/s1461145712000399
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.